This past September, a sub-agency of the Department of Health and Human Services (HHS) threatened to kick a pharmaceutical company out of Medicare because the company, in line with federal law, ...

Nonprofit healthcare centers are lobbying for a special exemption from a new Health and Human Services reimbursement review ...

Eli Lilly and Co. has restricted access to its drug discount program for safety-net hospitals, requiring them to submit ...

“When a program designed to deliver targeted assistance drives up system-wide costs, reform is no longer optional,” says health expert Sally Pipes. “It's necessary.” If a charity organization ...

Amid barbs over the shutdown and broader healthcare funding cuts, a Thursday committee hearing brought bipartisan agreement that more can be done to ensure the pricey drug subsidy program remains a ...

The rapid expansion of the federal 340B drug pricing program is significantly affecting Medicaid budgets, particularly in states where managed care plans oversee prescription drug benefits. New ...

In a letter last week, Johnson & Johnson informed certain hospitals of a major change it plans to make in the way it gives out discounts on two drugs. The company has found itself in opposition to ...

The Medicaid Drug Rebate Program and the 340B Drug Pricing Program are generally understood as separate efforts to promote drug affordability—one by directly subsidizing low-income patients through ...

$3M in Seed Funding and Proven Pilots Accelerate Path to Maximizing Essential Revenue for Healthcare Providers Serving Communities in Need Healthcare providers purchased a record $66 billion in drugs ...

Johnson & Johnson's rebate plan was widely denounced by the hospital industry, which warned that the delayed discounts would burden financially strapped hospitals. (Getty Images/Petmal) Drugmaker Eli ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...

At a time when healthcare executives are being asked to stretch scarce federal resources as far as possible, the 340B Drug Pricing Program is a much-appreciated lifeline. Despite the program being ...